Genentech, a member of the Roche Group, recently announced that its drug Actemra received approval from the U.S. Food and Drug Administration (FDA). Read More »

Albertsons Cos. plans on continued care for its customers as flu season approaches, reporting from its Boise, Idaho base that influenza vaccines are now in stock. Read More »

Newly compiled data from the Blue Cross Blue Shield Association indicates that the nation — particularly the state of Massachusetts — has substantially lowered the number of outpatient prescriptions for antibiotics, association sources announced recently from Boston. Read More »

Murray Hill, New Jersey-based surgical product producer and marketer C. R. Bard recently obtained premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for its Lutonix 035 drug coated balloon PTA catheter (DCB). Read More »

Drug developer Ligand Pharmaceuticals Inc. (LGND) of San Diego, California will receive $2 million plus royalties and other benefits from WuXi Biologics in a new licensing agreement involving an antibody technology, company officials announced recently. Read More »

Soliciting marketing approval for a medication addressing major depressive disorder, Alkermes PLC recently began a rolling submission of a New Drug Application regarding its ALKS 5461 product, expecting completion by the end of 2017. Read More »

Following President Donald Trump’s recent signing of the Food and Drug Administration Reauthorization Act, Biotechnology Innovation Organization officials released a statement of support celebrating the legislation reauthorizing prescription drug user fees. Read More »

The American Society for Parenteral and Enteral Nutrition (ASPEN) and Baxter International Inc. recently announced a comprehensive collaborative program entitled “Smart PN” that will provide healthcare professionals with educational tools for parenteral nutrition (PN) therapy. Read More »

AstraZeneca and Merck & Co. Inc. recently announced that their collaborative PARP inhibitor, Lynparza, received approval from the U.S. Food and Drug Administration (FDA). Read More »

To promote its once-daily medication designed to address migraine headaches and seizures, Minnesota-based Upsher-Smith Laboratories recently launched its redesigned website for Qudexy XR (topiramate) extended-release capsules — along with a branded program allowing better product accessibility. Read More »

Grifols, a provider of plasma-derived medicines, recently announced that its noninvasive workflow management system, Phocus Rx, is now used by three of the top five U.S. hospital information systems (HIS). Read More »

Biologics Inc., an oncology pharmacy services company under the McKesson Specialty Health umbrella, recently announced that Pfizer selected it to distribute Besponsa, a new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More »

The U.S. Food and Drug Administration has approved Ironwood Pharmaceuticals Inc.'s drug Duzallo, a once-daily oral treatment to fight hyperuricemia associated with gout in patients. Read More »

Avella Specialty Pharmacy has been recognized by Inc. Magazine as one of the 5,000 fastest-growing companies in the United States. Read More »

Trovagene Inc., a precision medicine biotechnology company, recently announced positive results from preclinical research of PCM-075 with a Histone deacetylase inhibitor in Non-Hodgkin Lymphoma cell lines. Read More »

Using a non-invasive solution for obesity and other metabolic and gastrointestinal disorders, Minnesota’s EnteroMedics recently revealed that MedStar Health achieved its first implant device for a military veteran in Maryland via the Veterans Choice Program. Read More »

Walgreens has been awarded the 2017 Infinity Arrow Award for Service and Take Back by the California Product Stewardship Council (CPSC) in recognition of the company’s Safe Medication Disposal program. Read More »

Amgen and Humana Inc. will collaborate on finding opportunities to improve health outcomes by analyzing the real-world health care experiences of Humana's 13 million members. Read More »

An innovative treatment for certain types of acute lymphoblastic leukemia (ALL).1 — Pfizer’s Besponsa (inotuzumab ozogamicin) — recently obtained approval from the U.S. Food and Drug Administration via its Breakthrough Therapy designation and Priority Review programs. Read More »

Jerusalem-based Teva Pharmaceutical Industries Ltd. recently began marketing generic Axiron (testosterone) topical solution CIII, 30 mg/1.5 mL, in the United States for treating adult males who are experiencing low testosterone levels due to medical reasons. Read More »